<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610800</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-21-0639</org_study_id>
    <nct_id>NCT05610800</nct_id>
  </id_info>
  <brief_title>Exenatide for Smoking Cessation and Prevention of Weight Gain</brief_title>
  <official_title>A Randomized Controlled Trial of Exenatide as an Adjunct to Nicotine Patch for Smoking Cessation and Prevention of Post-Cessation Weight Gain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if exenatide improves end-of-treatment smoking&#xD;
      abstinence rates and to determine if exenatide mitigates post-cessation weight gain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2022</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with 4-week continuous abstinence at 12 weeks post-target quit day as assessed by self-report timeline followback (TLFB) and verified by breath carbon monoxide (CO) level</measure>
    <time_frame>Week 15</time_frame>
    <description>Abstinence is defined as no smoking, not even a puff, as reported on TLFB between weeks 11 through 14 and biochemically verified (CO ≤ 5 ppm) at each visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight change in kilograms at 12 weeks post-target quit day</measure>
    <time_frame>Baseline, Week 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with 4-week continuous abstinence at 24 weeks post-target quit day as assessed by self-report timeline followback (TLFB) and verified by breath carbon monoxide (CO) level</measure>
    <time_frame>Week 26</time_frame>
    <description>Abstinence is defined as no smoking, not even a puff, as reported on TLFB between weeks 22 through 25 and biochemically verified (CO ≤ 5 ppm) at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change in kilograms at 24 weeks post-target quit day</measure>
    <time_frame>Baseline, Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in amplitude of the late positive potential evoked by visual stimuli</measure>
    <time_frame>Week 1, Week 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Weight Gain</condition>
  <arm_group>
    <arm_group_label>Exenatide, NRT, and Smoking Cessation Counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive once weekly exenatide injections, daily nicotine patches (NRT), and once weekly individual smoking cessation counseling sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, NRT, and Smoking Cessation Counseling</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive once weekly saline injections, daily nicotine patches (NRT), and once weekly individual smoking cessation counseling sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide 2 milligram (mg) Injection</intervention_name>
    <description>Exenatide will be purchased commercially as Bydureon for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 14 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.</description>
    <arm_group_label>Exenatide, NRT, and Smoking Cessation Counseling</arm_group_label>
    <other_name>Bydureon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.</description>
    <arm_group_label>Placebo, NRT, and Smoking Cessation Counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine patch</intervention_name>
    <description>Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.&#xD;
Participants who smoke &gt;10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.&#xD;
Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14.</description>
    <arm_group_label>Exenatide, NRT, and Smoking Cessation Counseling</arm_group_label>
    <arm_group_label>Placebo, NRT, and Smoking Cessation Counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking Cessation Counseling</intervention_name>
    <description>Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.</description>
    <arm_group_label>Exenatide, NRT, and Smoking Cessation Counseling</arm_group_label>
    <arm_group_label>Placebo, NRT, and Smoking Cessation Counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to sign and date an informed consent form, willing to comply with&#xD;
             all study procedures, and be available for the duration of the study&#xD;
&#xD;
          -  Male or female, 18-75 years of age&#xD;
&#xD;
          -  Have been smoking ≥5 cigarettes per day for at least 1 year and provide positive&#xD;
             cotinine test&#xD;
&#xD;
          -  Desire to quit smoking (defined as &quot;intend to quit within one month&quot;)&#xD;
&#xD;
          -  Have HbA1C levels between 5.7 and 6.4% and/or a body mass index of ≥25 kg/m2&#xD;
&#xD;
          -  Have vital signs as follows: resting pulse between 50 and 95 bpm, BP between 90-150&#xD;
             mmHg systolic and 45-95 mmHg diastolic&#xD;
&#xD;
          -  Have hematology and chemistry laboratory tests that are within reference limits&#xD;
             (±10%), with the following exception: pancreatic tests (lipase and amylase) must be&#xD;
             within normal limits&#xD;
&#xD;
          -  Agree (if the subject is female and of child-bearing potential) to use at least one of&#xD;
             the following methods of birth control from time of the first administration of the&#xD;
             study medication to at least 7 days post the last dose of the study medication, unless&#xD;
             the partner is surgically sterile (underwent vasectomy): oral contraceptives,&#xD;
             contraceptive sponge, patch, double barrier (diaphragm/spermicidal or&#xD;
             condom/spermicidal), intrauterine contraceptive system, etonogestrel implant,&#xD;
             medroxyprogesterone acetate contraceptive injection, hormonal vaginal contraceptive&#xD;
             ring, or complete abstinence from sexual intercourse.&#xD;
&#xD;
          -  Women of child-bearing potential must provide negative urine pregnancy tests prior to&#xD;
             randomization&#xD;
&#xD;
          -  Have a medical history and a brief physical examination demonstrating no clinically&#xD;
             significant contraindications for study participation, in the judgment of the Study&#xD;
             Physician and the PI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychoactive substance abuse or dependence (excluding nicotine dependence) within the&#xD;
             past 3 months (existing diagnosis or as determined by the structured interview)&#xD;
&#xD;
          -  Currently using chewing tobacco, snuff, snus or electronic cigarettes&#xD;
&#xD;
          -  Currently enrolled in a smoking cessation program/research study or using&#xD;
             pharmacotherapy for smoking cessation (NRT, varenicline, or bupropion)&#xD;
&#xD;
          -  Currently enrolled in a behavioral weight management plan/research study, or taking&#xD;
             medication used for weight management (i.e., orlistat,&#xD;
             lorcaserin,*naltrexone-bupropion, liraglutide, phentermine, benzhetamine,&#xD;
             diethylpropion, phendimetrazine), or medication known to impact weight (i.e.,&#xD;
             corticosteroids) *Note: Withdrawn from the market in Feb 2020, but some patients may&#xD;
             still be taking it&#xD;
&#xD;
          -  Currently using oral or injectable glucose lowering medications&#xD;
&#xD;
          -  Urine drug test positive, before randomization, for any of the following substances:&#xD;
             benzodiazepines, cocaine, opioids,*amphetamines, methamphetamine, buprenorphine,&#xD;
             barbiturates, 3,4-methylenedioxy-methamphetamine (MDMA), and/or THC. *Note: If&#xD;
             positive for opioids or oxycodone but recent opioid use for acute pain is reported by&#xD;
             the study candidate, then the candidate can be included at the discretion of the&#xD;
             Primary Investigator and/or Study Physician&#xD;
&#xD;
          -  Psychotic or bipolar disorder, or mood disorder with psychotic features, or eating&#xD;
             disorder (existing diagnosis or as determined by the structured interview)&#xD;
&#xD;
          -  Moderate to high risk for suicidality (as determined by the structured interview)&#xD;
&#xD;
          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine&#xD;
             neoplasia syndrome type 2 (MEN2)&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus (previously diagnosed or indicated by HbA1C level&#xD;
             of ≥6.5%)&#xD;
&#xD;
          -  Severe cardiovascular disease (history of myocardial infarction, life-threatening&#xD;
             arrhythmia, or worsening angina pectoris)&#xD;
&#xD;
          -  Severe gastrointestinal disease (i.e., severe gastroparesis)&#xD;
&#xD;
          -  Previous history of pancreatitis or risk of pancreatitis&#xD;
&#xD;
          -  Creatinine clearance &lt;45 mL/min or end stage renal disease (ESRD)&#xD;
&#xD;
          -  Previous medically adverse reaction to the study medications or nicotine&#xD;
&#xD;
          -  Women who are currently pregnant, or plan to become pregnant, or lactating, or of&#xD;
             childbearing potential and are not using medically accepted forms of contraception.&#xD;
             Medically accepted forms of contraception are specified in the inclusion criterion 8.&#xD;
&#xD;
          -  Current, anticipated, or pending enrollment in another research study over the next 6&#xD;
             months that could potentially affect subject safety and/or the study data/design as&#xD;
             determined by the PI and/or Study Physician&#xD;
&#xD;
          -  Unable to communicate (read, write, and speak) fluently in English&#xD;
&#xD;
          -  Have any illness or condition which in the opinion of the PI and/or the Study&#xD;
             Physician would preclude safe and/or successful completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luba Yammine, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luba Yammine, PhD</last_name>
    <phone>713-486-2737</phone>
    <email>Luba.Yammine@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Vincent</last_name>
    <phone>713-486-2803</phone>
    <email>Jessica.N.Vincent@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luba Yammine, PhD</last_name>
      <phone>713-486-2737</phone>
      <email>Luba.Yammine@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Vincent</last_name>
      <phone>713-486-2803</phone>
      <email>Jessica.N.Vincent@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 2, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>April 10, 2023</last_update_submitted>
  <last_update_submitted_qc>April 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Luba Yammine</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Cigarettes</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Cigarette Smoking</keyword>
  <keyword>Weight Gain Prevention</keyword>
  <keyword>Post-cessation Weight Gain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

